ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death - Wikidata - wikimedia - TriplyDB

ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death

ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death

http://www.wikidata.org/entity/Q37618997

about

The Dynamic Role of the IL-33/ST2 Axis in Chronic Viral-infections: Alarming and Adjuvanting the Immune Response The clinical application of mesenchymal stromal cells in hematopoietic stem cell transplantation Graft-versus-host disease biomarkers: omics and personalized medicine Acute graft-versus-host disease: a bench-to-bedside update.Functional Reconstitution of Natural Killer Cells in Allogeneic Hematopoietic Stem Cell Transplantation The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease Specific Etiologies Associated With the Multiple Organ Dysfunction Syndrome in Children: Part 1.Aqueous two-phase system patterning of detection antibody solutions for cross-reaction-free multiplex ELISA Biomarkers for fatal immune response to stem cell treatment could reduce mortality.The ST2/IL-33 Axis in Immune Cells during Inflammatory Diseases.The role of extracorporeal photopheresis in the management of cutaneous T-cell lymphoma, graft-versus-host disease and organ transplant rejection: a consensus statement update from the UK Photopheresis Society.Combining Flow and Mass Cytometry in the Search for Biomarkers in Chronic Graft-versus-Host Disease.Engraftment syndrome after allogeneic hematopoietic cell transplantation predicts poor outcomes.Etanercept plus topical corticosteroids as initial therapy for grade one acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.Prognostic biomarkers for acute graft-versus-host disease risk after cyclophosphamide-fludarabine nonmyeloablative allotransplantation.The interleukin-1 family: back to the future Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802.ST2: the biomarker at the heart of GVHD severity High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation.Various forms of tissue damage and danger signals following hematopoietic stem-cell transplantation.Histone deacetylase inhibition regulates inflammation and enhances Tregs after allogeneic hematopoietic cell transplantation in humans.A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study Baseline body mass index among children and adults undergoing allogeneic hematopoietic cell transplantation: clinical characteristics and outcomes.A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality.Opportunities and challenges of proteomics in pediatric patients: circulating biomarkers after hematopoietic stem cell transplantation as a successful example.A "window of opportunity" for patients with late-onset pulmonary dysfunction after allogeneic hematopoietic cell transplantation Identification of potential small molecule allosteric modulator sites on IL-1R1 ectodomain using accelerated conformational sampling method.Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantation The IL-33/ST2 axis augments effector T-cell responses during acute GVHD.Effectiveness and safety of lower dose prednisone for initial treatment of acute graft-versus-host disease: a randomized controlled trial.Plasma biomarkers of acute GVHD and nonrelapse mortality: predictive value of measurements before GVHD onset and treatment.Conformational Sampling and Binding Site Assessment of Suppression of Tumorigenicity 2 Ectodomain Intestinal Blautia Is Associated with Reduced Death from Graft-versus-Host Disease Advances in understanding the pathogenesis of graft-versus-host disease.Soluble DNAM-1, as a Predictive Biomarker for Acute Graft-Versus-Host Disease Biomarkers for Diagnosis and Prognosis of Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation A donor-specific epigenetic classifier for acute graft-versus-host disease severity in hematopoietic stem cell transplantation ST2 blockade reduces sST2-producing T cells while maintaining protective mST2-expressing T cells during graft-versus-host disease.How I treat acute graft-versus-host disease of the gastrointestinal tract and the liver.Proteomics analysis reveals a Th17-prone cell population in presymptomatic graft-versus-host disease.

P2860

Q26743383-646A9D97-367E-44F2-9906-79A7034E98B3 Q26748595-811CD145-F40F-47BF-AE36-54F8B85CDBD2 Q26824540-96F59E1C-13FD-4545-A1AA-B538CF801882 Q27687130-07D0A84E-551E-4592-9E15-652774795ADB Q28069682-F3C7EC58-3AD5-4406-868A-CA0A1750D5A5 Q28076264-F43D0A7E-8A5D-4B62-AB96-A043F5677D60 Q30253063-08E74BC3-18DD-4782-9F5B-3635FFD5CEC0 Q33554539-3B6A17D7-922A-4B3A-9171-E1BE20FAEEC2 Q33563471-A0FBC405-DBA1-4D31-A4E6-E78048BF4F51 Q33593742-A1D59419-910E-4F1A-A0D7-FE455E87ED56 Q33625948-2C740B05-7512-423C-A7BD-5032587FB94B Q33809599-176BAC2C-8B43-44AD-B1CC-DAEED5BA7783 Q34079430-68E793BC-E032-4EB0-9866-FB60768A25BA Q34093615-4C25BDBA-3881-4C8F-AA08-63D611F20ABD Q34325048-15F23DA4-A0E6-4A1A-861C-4CA5FD9FF881 Q34391415-98A79B7F-AA81-4F25-913D-757A77BA2FFE Q34551192-F88A4BC7-2F0E-4C7E-92A5-CC39D922FBA6 Q34802351-37A267FC-9241-4C3F-812D-C8FA9A963BFA Q34802425-DF11DF53-4439-42AF-B019-3FEE7BD3DA6F Q35022269-655C3976-858C-46D4-A997-F8899C390EDE Q35029450-0CDA3B0C-C511-4C04-A616-65F10CD5FF76 Q35120338-3DAF0E42-C97F-4051-B30A-3E3812AEF581 Q35152208-AD15DEF6-EC8A-4D51-912C-EBD7EFCF1927 Q35177453-FB456EB1-1C22-4BF3-BD15-6B4D01F2F5BF Q35180727-498EB2AA-06B5-4CD3-93E6-73F72C0EBDFD Q35445239-CB92FB47-8D6B-46FD-96B4-9E115BE42C68 Q35565839-63A963B6-E467-4F41-899B-8CEDC1812F43 Q35586614-6C09394E-0B42-4185-85E2-43BCC6E8DE65 Q35607302-57393393-8F53-42E1-920E-02F69C5BEFEB Q35669901-07BE2AA6-B279-4CB5-B653-15005F30D037 Q35820356-0E29B0EE-EE25-44A4-BEC4-922C17574A09 Q35886682-013E3F02-C856-43DB-9504-C6369CA3E8F4 Q35892249-B3EFBA19-F3AC-4C96-83BF-EAA262AC4F7D Q35971439-0FB4265D-1290-4EDA-B315-281156B60E1B Q36039542-5F6617F7-707B-4C3F-82B9-E72E26523AED Q36055238-72A454C2-1866-4A2F-9003-433A0066B1EE Q36376817-680CDF2D-9EF4-4493-9DBF-13CEB63B8AE8 Q36424657-CD322ED1-5CBC-48F0-A0E4-5D0D2B4218D1 Q36727862-2B7F3DA5-EC8F-4700-9400-C897077B1EC1 Q36904560-5E01C2DC-6182-4233-B5DA-041145288748

P2860

ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death

http://www.wikidata.org/entity/Q37618997

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on August 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death

@en

ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death.

@nl

type

label

ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death

@en

ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death.

@nl

prefLabel

ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death

@en

ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death.

@nl

P1433

Q37618997-60BDC706-A3C3-4C33-82D8-6B4101A74DD2

P1476

Q37618997-9F9060B3-A99B-4EBD-BE39-067E3E2E2EAB

P2093

Q37618997-08C47541-1BDF-430B-9A64-C31271AC38F4

Q37618997-144A250B-A3BF-4B3A-B6F7-72204930D6CC

Q37618997-2272F693-3458-424C-9C64-EE60C720B982

Q37618997-42C2F7A0-D011-4DA3-BC48-9074FFC8FC1E

Q37618997-50AAACD3-4433-4A3C-892A-2FEF33F878A9

Q37618997-68210401-3CF7-441B-B105-63345ED629F6

Q37618997-6B0C6891-0C20-4205-AAA3-ACD2514DFAA7

Q37618997-7EF2A57F-56E8-40E0-AFBB-3BC0263679A5

Q37618997-A1279833-9A82-48C5-96F0-7224026D9CD3

Q37618997-A202DD2A-BB56-4F19-B126-82063FDA2081

P2860

Q37618997-0048C197-1596-494A-991B-8E0E54869B67

Q37618997-17FA1034-8426-4960-BEBC-04AAD18F9A2B

Q37618997-1860813A-768B-43D5-8DD2-D3AE140E2CF5

Q37618997-1E7FB978-C3D3-45E3-B8A8-E7B750DF9E9A

Q37618997-29EF42E0-BD09-4852-A68F-DFEFEDF19CCF

Q37618997-2EA93498-6E94-4488-A35C-A526D34E4842

Q37618997-3C4C0DA4-D74E-405E-B073-9F64366025BF

Q37618997-42EC7FCC-42D1-4436-AF1D-AD19075D8EBB

Q37618997-44970C0C-BF54-44B6-938B-BFCEABF56D71

Q37618997-4D7868E4-055D-47DF-8C96-CF397363AE75

P304

Q37618997-A5F67B66-A3E6-478B-90BA-8FA07BD5B91E

P31

Q37618997-40349359-5011-4A49-A018-71283DAAFCEA

P356

Q37618997-C5D67201-FEE3-4004-8DEE-2BE6EB044F0F

P407

Q37618997-B3916169-377B-4E77-B40E-E0CE4C754050

P433

Q37618997-AA3FC36D-7EFD-4FF6-999B-6C69E622B802

P478

Q37618997-651223AB-07EE-4257-AC2D-F5FF212B367D

P50

Q37618997-480872B0-D18A-4C45-B024-320E080FD798

P577

Q37618997-6FA3C68E-DA5A-4452-BBD2-61537B9E6301

P698

Q37618997-F6D23A1B-6CBB-4AD6-AFCF-AC63C9DAB932

P932

Q37618997-F8EE7B9E-2BF0-41F6-8E6F-6CCD6A3B7693

P356

P1433

The New England Journal of Medicine

P1476

ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death

@en

P2093

Alice Chin

http://www.w3.org/2001/XMLSchema#string

Andrew C Harris

http://www.w3.org/2001/XMLSchema#string

Aurélie Gomez

http://www.w3.org/2001/XMLSchema#string

Chee-Hong Wong

http://www.w3.org/2001/XMLSchema#string

Daniel Couriel

http://www.w3.org/2001/XMLSchema#string

Hong Wang

http://www.w3.org/2001/XMLSchema#string

James L M Ferrara

http://www.w3.org/2001/XMLSchema#string

Jerome Ritz

http://www.w3.org/2001/XMLSchema#string

John E Levine

http://www.w3.org/2001/XMLSchema#string

Joseph H Antin

http://www.w3.org/2001/XMLSchema#string

P2860

IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines

Interleukin-1 in the pathogenesis and treatment of inflammatory diseases

Elafin is a biomarker of graft-versus-host disease of the skin

T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function

Secreted and membrane-bound isoforms of T1, an orphan receptor related to IL-1-binding proteins, are differently expressed in vivo

IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system

Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation

Prognostic value of response after upfront therapy for acute GVHD

Graft-versus-host disease treatment: predictors of survival.

Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop.

P304

529-539

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1213299

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

369

http://www.w3.org/2001/XMLSchema#string

P50

Sophie Paczesny

P577

2013-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23924003

http://www.w3.org/2001/XMLSchema#string

P932

3943357

http://www.w3.org/2001/XMLSchema#string